Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples